Presentation TCT 2015 Acute DAPT Decisions: Agent Selection and Whether to Load Presenter: George D. Dangas, Paul A. Gurbel October 13, 2015
Presentation TCT 2015 I Dont Believe DAPT Should Be Discontinued at or Before 12 Months After Elective DES Implantation! Presenter: Eric R. Bates, Spencer B. King III, Daniel I. Simon October 13, 2015
News Conference News TCT 2015 Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials October 13, 2015
Presentation TCT 2015 DAPT Duration Case 2: An Elderly Patient With CKD and Left Main Bifurcation Stenting Postdischarge Course Presenter: John A. Bittl, Gary L. Schaer, Gennaro Giustino October 12, 2015
Presentation TCT 2015 DAPT Duration Case 1: An Elderly Patient With CKD and Left Main Bifurcation Stenting In-Hospital Course Presenter: John A. Bittl, Gary L. Schaer, Gennaro Giustino October 12, 2015
Presentation TCT 2015 Is Dropping Aspirin the Magic Solution? Presenter: John A. Bittl, Gary L. Schaer, Pascal Vranckx October 12, 2015
Presentation TCT 2015 Risk vs Benefit: Can We Determine Which Patients Should Be Treated With Long-term DAPT? Presenter: John A. Bittl, Gary L. Schaer, Matthew T. Roe October 12, 2015
Presentation TCT 2015 Does PEGASUS Inform the Debate? Presenter: John A. Bittl, Gary L. Schaer, Stephen D. Wiviott October 12, 2015
Presentation TCT 2015 Debate: The Optimal Duration of DAPT After DES Is Less Than 12 Months for Most! Presenter: John A. Bittl, Gary L. Schaer, Tullio Palmerini October 12, 2015
Presentation TCT 2015 Debate: The Optimal Duration of DAPT After DES Is More Than 12 Months for Most! Presenter: John A. Bittl, Gary L. Schaer, Laura Mauri October 12, 2015
Presentation TCT 2015 HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Statistical Perspective Presenter: Bernard J. Gersh, William S. Weintraub, Stuart J. Pocock October 12, 2015
Presentation TCT 2015 HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Clinical/Trialist Perspective Presenter: Bernard J. Gersh, William S. Weintraub, Gregg W. Stone October 12, 2015
Presentation TCT 2015 DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset) Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr October 12, 2015
Presentation TCT 2015 DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl October 12, 2015
Presentation TCT 2015 DAPT Duration After DES: Does 1 Size Fit All? Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl October 12, 2015
News Industry News Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants October 12, 2015
News Conference News TCT 2015 ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years October 12, 2015
Presentation TCT 2015 Three to Six Months of DAPT Is My Practice Even in Very Complex Cases: Heres Why Presenter: Ricardo Lluberas, Roxana Mehran, Jamil Abdalla Saad, Fausto Feres October 11, 2015
Presentation TCT 2015 From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT? Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran October 11, 2015